BI 10773

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Randomised Evaluation of COVID-19 Therapy

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Empagliflozin in Patients With Cirrhosis and Ascites

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Safety and Efficacy of Empagliflozin in Hemodialysis

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

SGLTi, Hepatic Glucose Production and Ketogenesis

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

Empagliflozin Treatment in Kidney Transplant Recipients

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Therapy to Maintain Remission in Dilated Cardiomyopathy

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Polypill for Prevention of Cardiomyopathy

Ketones, SGLT2, HFrEF

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Prevention of Progression of Prediabetes, Obesity and CV Risk

Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients

Empagliflozin Reversal of Arterial StiffnEss in Aging

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Feasibility Trial for a Right Ventricular Failure Platform Trial

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

Randomized Trial of SGLT2i in Heart Transplant Recipients

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II

EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)

Improving Coronary Vascular Health in Women

The EMPA-FIT Study

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study

RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

SGLT2i, Hepatic Glucose Production, and SNS

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

SGLT2i, Pioglitazone, and Ketone Production in T2D

SGLT2i in Kidney Stones

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial

Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

SGLT2i Therapy in Islet Transplantation (SIT)

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

Effect of Empagliflozin on Inflammation

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Add-on Diuretics in Acute Decompensated Heart Failure

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

Glycemic Variability of Combination Therapies in T2DM

The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population

The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

DDI Between BI Empagliflozin (10773) and Verapamil

Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers

Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin

Drug Interaction Study of Digoxin and BI 10773

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

SGLT2 Inhibition and Left Ventricular Mass

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Empa/Lina FDC Food Effect Study (Japan)

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes

Cardiovascular Effects of Empagliflozine

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Empagliflozin vs Metformin in PCOS

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Characteristics of Empagliflozin Initiators

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Pharmacokinetic Evaluation of Empagliflozin

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

EMPRA (EMPagliflozin and RAs in Kidney Disease)

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Empagliflozin and Renal Oxygenation in Healthy Volunteers

Empagliflozin in Post-Transplantation Diabetes Mellitus

Impact of Empaglifozine on Cardiac Ectopic Fat

Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be Investigated

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Empagliflozin in Renal Transplant Recipients

Empaglifozin in Early Diabetic Kidney Disease

Empagliflozin and Hepatic Glucose Metabolism

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure

Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes

SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Empagliflozin and Sympathetic Nerve Traffic

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Comparative Effectiveness of Empagliflozin in the US

Performance Under SGLT-2-Inhibitors in Humans

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES

Empagliflozin Effect on Glucose Toxicity

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Empa PASS on Urinary Tract Malignancies

Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

EMPA Acute Heart Failure

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

The Effects of Empagliflozin on Arterial Wall Characteristics

Efficacy and Safety of Empagliflozin in NODAT

Regulatory Request NIS in Korea

Antidiabetic Drugs for Steatotic Liver Disease

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Prognostic Predictors of Response to Hypoglycemic Therapy

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Effect of Empagliflozin on Body Composition and Ketones

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Effect of Empagliflozin on Ventricular Repolarization.

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

SGLT2 Inhibitors in Glomerular Hyperfiltration

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

Short Term Effect of Empagliflozin in Hypertension

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

Pharmacological Reduction of Right Ventricular Enlargement

Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System

Empagliflozin and Cardiac Remodelling in People Without Diabetes

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

POST-CABGDM: Empagliflozin in Perioperative CABG

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)

Empagliflozin and Atrial Fibrillation Treatment

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Polypill Strategy for Heart Failure With Reduced Ejection Fraction

Combined Active Treatment in Type 2 Diabetes With NASH

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Follow-up of NAFLD Patients With MRI-PDFF

Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers

Empagliflozin in Adolescent Diabetes

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

Empagliflozin in Diuretic Refractory Ascites

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus

Empagliflozin for the Treatment of Postprandial Hypoglycemia

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Anti-diabetic Drugs and Fatty Liver Management

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

SNIFF - Combo INI+EMPA Trial

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Empagliflozin in Hypertrophic Cardiomyopathy

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

SGLT2 Inhibition: Uric Acid Excretion Study

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

HF Patients With LVADs Being Treated With SGLT2i

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Empagliflozin in Patients With Glomerulonephritis

Empagliflozin in Acute Heart Failure

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors

Cognitive Protective Effect of Newer Antidiabetic Drugs

Emp-Activity: Empagliflozin Functional Capacity

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Canagliflozin in Patients With Acute Decompansted Heart Failure

Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Impact of SGLT2 on Glucosuria in HNF1A-MODY

Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Use of Empagliflozin to Treat Prediabetes

Empagliflozin as a Novel Therapy in Refractory Ascites

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Empagliflozin in Pulmonary Arterial Hypertension

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy

Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

Effects of Acute and Chronic Empagliflozin Heart Failure

Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial

Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Empagliflozin in ESKD - A Feasibility Study

Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure

Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Empagliflozin in Heart Failure Dialysis Patients

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Initiation of ARNi and SGLT2i in Patients With HFrEF

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot

Empagliflozin to Prevent Post-Operative Atrial Fibrillation

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

EMPagliflozin After Aortic Valve Replacement

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

Treatment of Patients With Diabetic Kidney Disease

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

SGLT2 Inhibitors and Perioperative Period

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Use of SGLT2i in noHCM With HFpEF

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets

Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure

The Role of SGLT2i in Management of Moderate AS

To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers

The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure

Reducing Non-Alcoholic Steatohepatitis

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus

The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension

New Triple Therapy in Newly Diagnosed Type 2 Diabetes

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food

Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Metabolic Surgery for Atrial Fibrillation Elimination

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

Vascular Effects of SGLT2i in Non-diabetic CKD

Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

Empagliflozin on Patients With Preserved Heart Failure

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers

A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets